IMMUNOME INC (IMNM)

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wednesday 11/27 Insider Buying Report: IMNM, ACDC

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Bargain Hunters Take Note: Insider Cluster-Buying At IMNM

Oversold Conditions For Immunome (IMNM)

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome (IMNM) Shares Cross Above 200 DMA

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Immunome Breaks Above 200-Day Moving Average - Bullish for IMNM

Immunome Stock Sees RS Rating Jump To 91

Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.

IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024

IMNM stock results show that Immunome missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immunome (NASDAQ:IMNM) just reported results for the second quarter of 2024.Imm...

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Nectin Therapeutics Licenses Novel Antibodies to Immunome

/PRNewswire/ -- Nectin Therapeutics, Ltd., a biotechnology company developing novel immunotherapies and antibody drug conjugates (ADC) to address tumor...

Immunome Appoints Phil Tsai as Chief Technical Officer

Oversold Conditions For Immunome (IMNM)

Notable Two Hundred Day Moving Average Cross - IMNM

Wednesday 5/22 Insider Buying Report: IMNM, CMI

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Investors Snag IMNM 25.5% Cheaper Than Its Secondary Stock Offering

IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024

IMNM stock results show that Immunome beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.